Maze Therapeutics CEO Jason Coloma sells $932,259 in Maze shares

Maze Therapeutics CEO Jason Coloma disposed of significant holdings in the company's common stock on October 1, 2026. The total value of the shares sold amounted to $932,259. Coloma's sales comprised two separate transactions, with 2,593 shares sold at prices between $26.645 and $27.46 each, and a larger disbursement of 31,908 shares traded at rates from $26.585 to $27.47.

Both sales were executed under a pre-established Rule 10b5-1 trading plan initiated by Coloma on February 6, 2026. Following these sales, Coloma's direct ownership of Maze shares was reduced to 27,362, with an additional 15,558 shares belonging to The Coloma 2021 Irrevocable Trust, and a further 191,447 shares held by The Coloma Family Trust, also co-trusteed by Coloma and his spouse.

Despite these sales, Maze's stock price hovered around $27.53, a level deemed overvalued by InvestingPro, which places the company among those on a list of the most overvalued stocks. The company's stock has experienced a decline of 33.55% year-to-date, even as it has shown recent momentum. This article was produced with the aid of AI technology and reviewed by an editor.